Biosimilars Regulatory Update:
an evolving landscape

They’re costly to develop, fraught with potential patient safety concerns and subject to regulations that have yet to be written.

Yet for the pharmaceutical industry, biosimilar monoclonal antibodies (mAbs) represent a potential treasure chest of new drugs—and bigger profits.

Yet while the industry is poised to move swiftly in developing new drugs that will plump weak pipelines, regulators have been cautious about instituting guidelines for what is a dynamic and evolving field.

All that is about to change, however, with the European Medicine Agency’s (EMA) recent release of draft guidelines for mAb development that make the prospect of lower cost, robustly-tested biosimilars a real possibility. Now full-fledged pioneers in the area, the EMA’s guidelines are expected to be finalized in May 2011, and may well forge a path for the United States to follow.

Although the Federal Drug Administration (FDA) has uncharacteristically trailed behind in the biosimilar race, it now has them firmly on the agenda. An approach to approving biosimilars through an abbreviated pathway is now being developed following a period of public consultation.

In Biosimilars Regulatory Update: an evolving landscape, FirstWord offers a timely and thorough analysis of Europe’s new biosimilar draft guidelines, cast against the FDA’s consideration of just how biosimilar approval should proceed in the US.

The fascinating report offers clear and critical insights into an otherwise complex topic, at a time when the industry must keep pace more than ever with developments. Containing a full breakdown of clinical and non-clinical requirements for Europe, immunogenicity assessments, a guide to the US position and a section on pharmacovigilance, the report is an accurate state-of-play on a dynamic and shifting environment.

The report offers:

  • A concise and timely overview of European and US developments
  • A comprehensive review of EMA and FDA consultations and guidelines

Key features

  • Analysis of the European regulations and potential moves by the US
  • Complete and concise review of guideline specifics including safety requirements
  • Examination of key issues facing biosimilar developments and how legislation may ease barriers
  • Analysis of immunogenicity assessments
  • Sections on pharmacovigilance and issues surrounding biosimilarity

Biosimilars Regulatory Update: an evolving landscape costs $395 a copy. Click here to order

For multi-user access, click here to contact us.

Publication date:
 February, 2011
Product code:
$395 Single User License

Single user licenseAuthorizes use by the person placing the order only.

$1,975 Team License

Team licenseAuthorizes use by up to 10 employees of the Licensee who work within the same team or functional business unit.

$5,925 Global License

Global licenseAuthorizes use by any employee of the Licensee, including employees of the Licensee's affiliates.

Order Now

Content Highlights

  • Executive summary
  • Europe on the way to biosimilar monoclonal antibodies
    > Non-clinical and clinical requirements
    > Non-clinical studies
    > In vitro pharmacodynamic studies
    > Identification of factors important for in vivo non-clinical studies
    > Clinical studies
    > Pharmacokinetics
    > Pharmacodynamics
    > Clinical efficacy
    > Clinical safety
    > Extrapolation of indications
    > Immunogenicity assessment
    > Immunogenicity and biosimilars
    > Approaches to predict and reduce immunogenicity
    > Clinical consequences of immunogenicity
    > Assessing immunogenicity
    > Screening and confirmatory assays
    > mAb presence in samples
    > Controls
    > Assessing the neutralizing capacity of induced antibodies
    > Different risk classes
    > A risk-based approach to developing biosimilar mAbs
  • US takes first step towards a biosimilars approval pathway
    > Guidance documents
    > User fees
    > Exclusivity
    > Data versus market exclusivity
    > Potential for evergreening
    > Comments from consultation
    > Biosimilarity
    > Is a demonstration of biosimilarity currently feasible?
    > How should biosimilarity be evaluated?
    > To what degree are clinical trials required?
    > Clinical trial design
    > Clinical trial endpoints
    > Extrapolation of data to other disease indications
    > Interchangeability
    > Product drift
    > Use of a non-US reference product
    > Pharmacovigilance
    > Unique international non-proprietary names for biosimilars?
    > Biosimilar drug labeling
    > Pharmacovigilance
    > Biosimilars approval in the US likely to be guidance-driven
  • Appendix
    > Abbreviations
    > US speaker details